KILITCH DRUGS (INDIA) LTD - STOCK OF THE WEEK

Dear Investor friends, Today i am expressing my view on one pharma stock

KILITCH DRUGS (INDIA) LTD

Kilitch Drugs (India) Limited is an ISO 9000, 13000 India-based company, which is engaged in the development and operations of its pharmaceutical business. Company is founded in 1978.

Kilitch Drugs (India) (KDIL) went public in Feb.94 to set up a pharmaceutical formulation plant at Thane to manufacture pharmaceutical products in the form of tablets, capsules, liquid orals, ointments, creams and injectables. Even before the plant was commissioned, the company came out with a rights issue in Oct.95 to expand the injectable capacity. Commercial production at the plant at Thane commenced in 1996. The company has two divisions - O T C and ethical.

Today with close to four decades of successful pharmaceutical solutions, company now focused on Africa and have expanded its footprint across key African countries. New markets, partnerships and enhancements have made Kilitch stronger and more customer-centric. 

PRODUCTS

Company products are fall under four category

1.    Parenteral Solutions

2.    Effervescent

3.    Nutritional products

4.    Medical devices.

Following are the few products of the company.

ROIPAR

Paracetamol is one of the most widely used drug. Using advanced manufacturing technology ROIPAR has been designed for faster & more satisfying relief of pain and fever for the patients. The effervescence tablets of ROIPAR disperses quickly in water.

ROIVIT

Roivit is the one of the company brand as an energy booster for every one ensuring that they live an active life style. It has various benefits which shall boost your immunity and ensure a healthy life. By taking Roivit multivitamin the energy producing activities will be better. It improves your vitality, and gives you energy which ensures you are active all day.

PH 7

This product is to fight against indigestion. PH-7 works as an antacid which reduces the acid content of the stomach thereby relieving indigestion. It make urine alkaline thus relieve associated discomfort making it valuable in the treatment of urinary tract infection.

 C Seal

C-SEAL topical skin adhesive is indicated for topical application only, to hold Closed easily approximated skin edges of wounds from surgical Incisions, including punctures from minimally invasive surgery and simple thoroughly cleaned, trauma induced lacerations.

SRO Kit

This is for Oral rehydration salts having orange flavour along with 10 zinc sulphate dispersible tablets. WHO recommends to provide children with 20 mg per day of zinc supplementation for 10-14 days together with ORS in the treatment for childhood diarrhoea.

9- VIT

9-VIT is indicated in surgery, extensive burns, fractures, and other trauma, severe infectious diseases and comatose states which may provoke a stress situation with profound alterations in the body's metabolic demands and consequent tissue depletion of nutrients.

H PURE

This product is for fast relief from Sore Throat & Cough. In Ayurvedic medicine, turmeric is a well-documented treatment for various respiratory conditions (eg. asthma, bronchial hyperactivity, and allergy), as well as for liver disorders, anorexia, rheumatism, diabetic wounds, runny nose, cough and sinusitis.

CLIENTS

Company has strong customer base from the major pharma companies. Following are the few major clients of the company.

Company website: Click here

FINANCIALS AND OUTLOOK

Company shares are trading in NSE and BSE.

Promoter holding : 64.5% as on sept qtr

Company posted 14.95 Cr top line in sept Qtr.

Net profit is 2.23 Cr bottom-line in sept Qtr.

Book value: RS 89.25 Rs

Debt  to Equity: 0.01

Virtually debt free

Stock is trading at Rs 87

Company stocks are trading lower than the book value.

Company is having a strong customer base, and leading in this domain.

Company’s overseas business especially Africa is growing very fast.

Considering this performance, stock is expected to give handsome returns to the investors in coming days.

NOTE : THE ABOVE IS NOT A RESEARCH REPORT NOR A RECOMMENDATION  BUT INFORMATION AS AVAILABLE ON PUBLIC DOMAIN. 

Registration status with SEBI: I am not registered with SEBI under the (Research Analyst) regulations 2014 and as per clarifications provided by SEBI: “Any person who makes recommendation or offers an opinion concerning securities or public offers only through public media is not required to obtain registration as research analyst under RA Regulations”